Implant Sciences Aims At Orthopedic, Brachytherapy, Stent Markets With IPO
This article was originally published in The Gray Sheet
Implant Sciences Corp., currently developing a method for embedding radioactivity into coronary stents in partnership with Guidant, is looking to raise $6-7 mil. in an initial public offering this spring, according to a prospectus filed Feb. 10 with the Securities and Exchange Commission.
You may also be interested in...
Biomet plans to evaluate its ceramic-on-ceramic hip prosthesis in a 100-patient clinical study that is scheduled for completion in mid-2002, company officials report.
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.